These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18031845)

  • 1. Two-year outcome of the use of paclitaxel-eluting stents in aorto-ostial lesions.
    Tsuchida K; Daemen J; Tanimoto S; García-García HM; Kukreja N; Vaina S; Ong AT; Sianos G; de Jaegere PP; van Domburg RT; Serruys PW
    Int J Cardiol; 2008 Oct; 129(3):348-53. PubMed ID: 18031845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results and predictors of angiographic restenosis and long-term adverse cardiac events after drug-eluting stent implantation for aorto-ostial coronary artery disease.
    Park DW; Hong MK; Suh IW; Hwang ES; Lee SW; Jeong YH; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2007 Mar; 99(6):760-5. PubMed ID: 17350360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and long-term outcomes of drug-eluting stent implantations in aorto-ostial, left anterior descending artery-ostial, and nonostial lesions.
    Hsieh IC; Chen CC; Chang SH; Hsieh MJ; Wang CY; Lee CH; Lin FC
    Catheter Cardiovasc Interv; 2013 Nov; 82(5):727-34. PubMed ID: 23592601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term outcomes of intracoronary stenting in aorto-ostial, left anterior descending artery-ostial and nonostial stenoses.
    Huang HL; Hsieh IC; Chang SH; Chang HJ; Chen CC; Hung KC; Wen MS; Wu D
    Int J Cardiol; 2005 Jun; 101(3):391-7. PubMed ID: 15907406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited.
    Hoye A; van Mieghem CA; Ong AT; Aoki J; Rodriguez Granillo GA; Valgimigli M; Tsuchida K; Sianos G; McFadden EP; van der Giessen WJ; de Feyter PJ; van Domburg RT; Serruys PW
    Int J Cardiovasc Intervent; 2005; 7(1):36-40. PubMed ID: 16019613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.
    Levisay JP; Price MJ; Shaba W; Lee SS; Stinis CP; Miller L; Teirstein PS
    J Invasive Cardiol; 2010 May; 22(5):216-9. PubMed ID: 20440037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stent implantation of saphenous vein graft aorto-ostial lesions in patients with unstable ischemic syndromes: immediate angiographic results and long-term clinical outcome.
    Rechavia E; Litvack F; Macko G; Eigler NL
    J Am Coll Cardiol; 1995 Mar; 25(4):866-70. PubMed ID: 7884089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis.
    Azzarelli S; Amico F; Galassi AR; Giacoppo M; Argentino V; Fiscella A
    J Invasive Cardiol; 2008 Feb; 20(2):62-6. PubMed ID: 18252969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.